

F₁
wherein the non-cell binding antibody (1) has affinity for antigen binding reduced to 50% or less as compared to the therapeutic antibody due to the modification(s), (2) comprises at least one epitope present in the therapeutic antibody which induces an immune response, and (3) induces immunological tolerance to the therapeutic antibody, and

wherein said non-cell binding antibody is not a mixed molecule antibody having an H or L chain of a therapeutic antibody paired with an L or H chain or an unrelated antibody.

64. (Amended) A method of producing a non-cell binding antibody fragment for inducing immunological tolerance to a therapeutic antibody having affinity for a cell-surface antigen, said method comprising:

F₂
fragmenting the therapeutic antibody to obtain the non-cell binding antibody fragment, the non-cell binding antibody fragment (1) having affinity for antigen binding reduced to 50% or less as compared to the therapeutic antibody due to the fragmentation, (2) comprising at least one epitope present in the therapeutic antibody which induces an immune response, and (3) inducing immunological tolerance to the therapeutic antibody.

Kindly add new Claims 73-75.

73. (New) The method as claimed in Claim 26, wherein the affinity for antigen binding of the non-cell binding antibody is reduced such that said antibody does not show detectable binding to antigen in ELISAs at 100 times the minium concentration at which binding of the therapeutic antibody is detectable.

F₃
74. (New) The method as claimed in Claim 73, wherein said antibody does not show detectable binding to antigen in ELISAs at 1,000 times the minium concentration at which binding of the therapeutic antibody is detectable.

75. (New) The method as claimed in Claim 74, wherein said antibody does not show detectable binding to antigen in ELISAs at 10,000 times the minium concentration at which binding of the therapeutic antibody is detectable.
